Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05906524
Other study ID # KD6001CT03
Secondary ID
Status Not yet recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date April 15, 2024
Est. completion date December 31, 2025

Study information

Verified date May 2023
Source Shanghai Kanda Biotechnology Co., Ltd.
Contact Chi Zhang
Phone +8615800854907
Email zhangchi@kandatech.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase 1b/2, open label study to evaluate the safety, tolerability, pharmacokinetics and initial efficacy of KD6001 in combination with Tislelizumab ± Bevacizumab in patients with Advanced HCC and Other Solid Tumors.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 85
Est. completion date December 31, 2025
Est. primary completion date April 30, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Main Inclusion Criteria: 1. Being voluntary to sign the informed consent form. 2. Male or female, aged = 18 years. 3. Patients whose estimated survival time is more than 3 months. 4. Eastern Cooperative Oncology Group (ECOG) performance status score 0 or 1. 5. At least one measurable lesion is used as the target lesion according to the Response Evaluation Criteria in Solid Tumors Version 1.1(RECIST V1.1). 6. Histologically or cytologically confirmed advanced solid tumors. Have a current liver function meeting Child Pugh Class A in patients with HCC. Part A: Advanced solid tumors. PartB/C: HCC. 7. Patients will agree to provide tumor tissue samples. 8. The results of laboratory examination during the screening period suggest that the subjects have good organ function. 9. Male subjects with reproductive ability or female subjects with the possibility of pregnancy use effective contraceptive methods. 10. Good compliance and follow-up. Main Exclusion Criteria: 1. History of malignancy other than the disease under study within 5 years prior to screening,except those malignancies that are expected to be cured after treatment. 2. Systematic treatment with antitumor drugs within 4 weeks prior to the start of this study. 3. Prior treatment with anti-CTLA-4 antibody. 4. Adverse events caused by prior treatment did not recovered to NCI-CTCAE v5.0 grade 1 and below. 5. Subjects with CNS metastases or leptomeningeal disease. 6. Subjects with an active, known or suspected autoimmune disease. 7. Subjects with acute or chronic active hepatitis B or hepatitis C. 8. Has histological or cytological diagnosis of fibrolamellar HCC, sarcomatoid HCC or mixed cholangiocarcinoma. 9. Subjects suffers from severe cardiovascular and cerebrovascular diseases. History or evidence of bleeding diathesis or significant coagulopathy at risk of bleeding. 10. Subjects with an active infection requiring systemic treatment. 11. Known history of testing positive for human immunodeficiency virus (HIV). 12. Subjects known to have active tuberculosis (TB). 13. Pregnant or breastfeeding females. 14. Known to be allergic to KD6001, tislelizumab, bevacizumab or its components.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
KD6001
KD6001 will be administered intravenously.
Tislelizumab
Tislelizumab will be administered intravenously.
Bevacizumab
Bevacizumab will be administered intravenously.

Locations

Country Name City State
China Zhongshan Hospital Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Shanghai Kanda Biotechnology Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants with Dose Limiting Toxicities (DLTs) DLTs will be assessed during the dose-escalation phase and are defined as the following treatment-related adverse events occurring within a total of 21 days after the first trial administration. Up to Day 21
Primary The incidence and safety profile of participants with adverse events (AEs), serious adverse events(SAE), and immune-related adverse event(irAE) Evaluate the adverse events (AE) according to National Cancer Institute Common Terminology Criteria for Adverse Events v5.0 (NCI CTCAE 5.0). Baseline to study completion up to 2 years
Secondary The antitumor activity of KD6001 in combination with Tislelizumab ± Bevacizumab measured by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Number of participants with response according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria. Baseline to study completion up to 2 years
Secondary Maximum Plasma Concentration [Cmax] The PK profile of KD6001 in combination with Tislelizumab ± Bevacizumab. Baseline to study completion up to 2 years
Secondary Time to reach maximum serum concentration (Tmax) The PK profile of KD6001 in combination with Tislelizumab ± Bevacizumab. Baseline to study completion up to 2 years
Secondary Half-life (T1/2) The PK profile of KD6001 in combination with Tislelizumab ± Bevacizumab. Baseline to study completion up to 2 years
Secondary Area under blood concentration-time curve(AUC0-T and AUC0-8) The PK profile of KD6001 in combination with Tislelizumab ± Bevacizumab. Baseline to study completion up to 2 years
Secondary Apparent volume of distribution (Vd) The PK profile of KD6001 in combination with Tislelizumab ± Bevacizumab. Baseline to study completion up to 2 years
Secondary The immunogenicity of KD6001 in combination with Tislelizumab ± Bevacizumab Including the incidence of ADA positive. For ADA positive patients, the incidence of neutralizing antibody (Nab) will be analyzed. Baseline to study completion up to 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT04045496 - A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors Phase 1
Terminated NCT02709889 - Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06022757 - Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19) Phase 1/Phase 2
Not yet recruiting NCT06027983 - Chimeric Receptor T Cells With Trastuzumab in HER2+ Advanced Breast Cancer and Other Solid Tumors Phase 1/Phase 2
Recruiting NCT05332574 - A Safety, Tolerability, PK and Preliminary Activity Study of GB263T in Advanced NSCLC and Other Solid Tumor Phase 1/Phase 2
Recruiting NCT05788484 - A Study of CDX-585 in Patients With Advanced Malignancies Phase 1
Completed NCT04834778 - A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD) Phase 1
Recruiting NCT03947385 - Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions Phase 1/Phase 2
Completed NCT02819843 - A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors Phase 2
Recruiting NCT04121286 - A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China Phase 1
Recruiting NCT05877599 - A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation Phase 1
Recruiting NCT05631964 - Phase I Clinical Study of BL-M07D1 in Locally Advanced or Metastatic Digestive Tract Tumors and Other Solid Tumors Phase 1
Terminated NCT02607813 - Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations Phase 1
Recruiting NCT04256707 - Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment Phase 1/Phase 2
Terminated NCT05121948 - A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) Phase 1
Recruiting NCT06438783 - TQB2928 Injection Combined Anlotinib Hydrochloride Capsule in Recurrent/Metastatic Osteosarcoma and Other Solid Tumors Phase 1
Recruiting NCT05393427 - A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors Phase 1
Completed NCT02573259 - A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors Phase 1
Terminated NCT00064636 - Phase I Dose Escalation Study of VELCADE Plus Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors Phase 1
Completed NCT03329950 - A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies Phase 1